ADAnil K. D'Cruz

Anil K. D'Cruz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anil K. D'Cruz has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience

    by Tejpal Gupta, Jai Prakash Agarwal, Sarbani Ghosh-Laskar, Purvish M Parikh, Anil K D'Cruz, Ketayun A Dinshaw

    Background: The dominant pattern of failure for squamous cell carcinoma of head and neck remains loco-regional, although distant metastases are now being increasingly documented. Radical radiotherapy with concurrent chemotherapy is contemporary standard of care in the non-surgical management of these loco-regionally advanced cancers, based on large randomized controlled trials utilizing high-dose cisplatin (80–100 mg/m2) cycled every three-weekly during definitive radiotherapy. Although efficacious, this is associated with high acute morbidity necessitating intensive supportive care with attendant resource implications. The aim of this retrospective study was to assess the efficacy and acute toxicity of an alternative schedule i.e. concurrent weekly cisplatin-based radical radiotherapy and it's potential to be an optimal regimen in advanced head and neck cancers. Methods: Outcome data of patients with Stage III & IV head and neck squamous cell carcinoma, excluding nasopharynx, planned for radical radiotherapy (66–70 Gy) with concurrent weekly cisplatin (30 mg/m2) treated in a single unit between 1996–2004 was extracted. Results: The dataset consisted of 264 patients with a median age of 54 years. The median radiotherapy dose was 70 Gy (range 7.2–72 Gy) and median number of chemotherapy cycles was 6 (range 1–7). Two-thirds (65%) of patients received ≥85% of planned cisplatin dose. With a mean follow-up of 19 months, the 5-year local control; loco-regional control; and disease free survival was 57%; 46%; and 43% respectively. Acute grade 3 or worse mucositis and dermatitis was seen in 77 (29%) and 92 (35%) patients respectively, essentially in patients receiving doses ≥66 Gy and 6 or more cycles of chemotherapy. Other toxicities (hematologic, nausea and vomiting) were mild and self-limiting. Overall, the acute toxicity of this concurrent weekly chemo-radiation regimen though mildly increased did not mandate intensive supportive care. Stage grouping, primary site, and intensity of treatment were significant predictors of loco-regional control and disease free survival. Conclusion: Radical radiotherapy with concurrent weekly cisplatin has moderate efficacy and acceptable acute toxicity with potential to be an optimal regimen in loco-regionally advanced squamous cell carcinoma of the head and neck, particularly in limited-resource settings. Stage grouping, primary site, and treatment intensity are important determinants of outcome.


  • PET‐CT in recurrent head neck cancers: A study to evaluate impact on patient management

    by G.H. Pantvaidya, J.P. Agarwal, M.S. Deshpande, V. Rangarajan, V. Singh, A. Kakade, A.K. D'CRuz

    Background and Objectives: PET‐CT has shown promise in the management of head neck cancers. However, there have been only few studies evaluating its impact on management of patients with recurrent cancers in the presence of available clinicoradiologic methods of assessment. We conducted this study to assess the same in patients with suspected recurrent head and neck cancer.Methods: Case histories were presented to two oncologists, who were blinded to PET‐CT reports. Treatment plans were made by these oncologists based on clinical findings and other conventional imaging. These plans were then compared to the actual treatment received by patients after PET‐CT. Any change was recorded as “change in management.”Results: Forty‐nine patients with suspected recurrent head and neck cancer were evaluated in the study. Overall, there was a 38.7% change in management because of the addition of PET‐CT to conventional methods of assessment. Eight patients (16.3%) had a major change in therapy while in 11 patients (22.4%), diagnostic procedures like endoscopies, biopsies and examination under anesthesia were avoided.Conclusion: In our study, PET‐CT had a significant impact on the management of patients with suspected recurrent head neck cancer. J. Surg. Oncol. 2009;100:401–403.


  • Elective neck dissection for the management of the N0 neck in early cancer of the oral tongue: Need for a randomized controlled trial

    by Anil K. D'Cruz, Ravichand C. Siddachari, Rohan R. Walvekar, Gouri H. Pantvaidya, Devendra A. Chaukar, Mandar S. Deshpande, Prathamesh S. Pai, Pankaj Chaturvedi

    Background: The aim of this study is to determine the need for a randomized controlled trial in order to define the role of an elective neck dissection (END) in the treatment of early tongue cancers.Methods: We present a large retrospective analysis of patients with T1‐2 N0 squamous cell cancers of the oral anterior tongue treated at a single institution. A total of 359 eligible patients with early tongue cancers were divided into 2 groups: END and wait and watch (WW). An analysis for survival outcomes and prognostic factors was conducted.Results: The estimated 3‐ and 5‐year disease‐free survival for the END group was 76% and 74% versus 71% and 68% for the WW group, respectively (p = .53). The 3‐ and 5‐year overall survival (OS) rate for the END group was 69% and 60% versus 62% and 60% for the WW group, respectively (p = .24). Tumor grade and perineural invasion were independent predictors of recurrence.Conclusion: END did not impact disease‐free or OS. Current literature still remains divided on this issue emphasizing the need for a randomized controlled trial. © 2009 Wiley Periodicals, Inc. Head Neck 2009


  • Open Access

    A unique RET EXON 11 (G691S) polymorphism in an Indian patient with a collision tumor of the thyroid

    by Bharat Rekhi, Rakesh R Badhe, Maria Desouza, Devendra Chaukar, Anil K D'Cruz, Suprita Arya, S V Kane

    Collision tumors of the thyroid are rare, with occasional reports dealing with their genetic analysis.


    • 1 September 2005
      • Vol. 122  (3) , 196-8

    Optimizing treatment in head and neck cancers -- are molecular markers the answer?

    by Anil K D'Cruz, Rita Mulherkar

  • Open Access

    Split therapy: Planned neck dissection followed by definitive radiotherapy for a T1, T2 pharyngolaryngeal primary cancer with operable N2, N3 nodal metastases—A prospective study

    by A.K. D'Cruz, G.H. Pantvaidya, J.P. Agarwal, D.A. Chaukar, K.A. Pathak, M.S. Deshpande, P.S. Pai, P. Chaturvedi, K.A. Dinshaw

    Background The management of patients with a small pharyngolaryngeal cancer (T1 and T2) with large nodal metastases is a subject of debate. We present data on the feasibility and outcome of treating these patients with surgery for the nodal metastases followed by definitive radiotherapy. Methods Prospective study of 59 patients of small pharyngolaryngeal primary squamous carcinomas with operable (N2/N3) nodal metastasis treated with neck dissection followed by radiotherapy. Results Complete nodal clearance was achieved in 54 (90%). The mean nodal size was 4 cm and extranodal extension was seen in 88% of patients in the study group. There were no significant postoperative complications. Median interval between surgery and radiotherapy was 23 days. Forty‐nine patients (83%) started their RT within 6 weeks of surgery. With a median follow‐up of 25 months, the disease free and overall survival was 54% and 60% (5 years). Conclusion The management of patients with a radiocurable pharyngolaryngeal primary with large nodes by this approach is a feasible option with adequate control and survival. J. Surg. Oncol. 2006;93:56–61.


  • mTHPC‐mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients

    by Anil K. D'Cruz, Martin H. Robinson, Merrill A. Biel

    Background.: The aim of this multicenter study was to assess tumor response, clinical quality‐of‐life benefit, survival, and safety after treatment with mTHPC in patients with recurrent/refractory squamous cell carcinoma of the head and neck unsuccessfully treated or unsuitable for treatment with conventional modalities.Methods.: One hundred twenty‐eight patients were treated with mTHPC followed, 96 hours later, by illumination of the tumor surface with 652‐nm laser light. Tumor response was assessed with WHO criteria and tumor mass reduction from baseline. Clinical quality‐of‐life benefit was based on the University of Washington Quality‐of‐Life questionnaire.Results.: By use of WHO criteria, 38% of evaluable patients achieved an overall tumor response, and 16% achieved a complete tumor response. Forty‐three percent of assessable lesions achieved 100% tumor mass reduction, and 58% achieved 50% or greater tumor mass reduction. Fifty‐three percent of evaluable patients experienced significant clinical quality‐of‐life benefit. Subset analyses revealed two subgroups in which significantly better responses were seen in patients with tumors 10 mm or less in depth and patients with fully illuminated lesions. In patients fulfilling both categories, overall tumor response was 54%, complete tumor response was 30%, and 61% demonstrated significant clinical quality‐of‐life benefit. Median survival was significantly better in responders. No major toxicities were detected.Conclusions.: Patients with advanced cancer of the head and neck, who have exhausted other treatment options, can achieve significant clinical benefit and improvement in quality of life with mTHPC. © 2004 Wiley Periodicals, Inc. Head Neck 26: 232–240, 2004